Zobrazeno 1 - 10
of 419
pro vyhledávání: '"Michael R. Boyd"'
Autor:
Jeremy B. Foote, Tyler E. Mattox, Adam B. Keeton, Forrest Smith, Kristly L. Berry, Antonio B. Ward, Karina J. Yoon, Sujith Sarvesh, Ganji P. Nagaraju, Yulia Maxuitenko, Xi Chen, Jacob Valiyaveettil, Julienne L. Carstens, Jennifer Yang, Donald J. Buchsbaum, Gang Zhou, Elmar Nurmmedov, Ivan Babic, Vadim Gaponenko, Hazem Abdelkarim, Michael R. Boyd, Bassel F. El-Rayes, Gary A. Piazza
Here we describe a novel class of pan-RAS inhibitor with highly potent and selective anticancer activity by killing cancer cells harboring mutations in RAS or with constitutively activated RAS resulting from mutations in upstream signaling components
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d76ea95ba86d6555f147a6ab3d6b4a1
https://doi.org/10.1101/2023.05.17.541233
https://doi.org/10.1101/2023.05.17.541233
Autor:
Giuditta De Lorenzo, Victoria A. Graham, Rafael A. Larocca, Jennifer Carmichael, Arvind H. Patel, Monica Poggianella, Stephen Findlay-Wilson, Cesar Lopez-Camacho, Wanwisa Dejnirattisai, Gavin R. Screaton, Emma Rayner, Arturo Reyes-Sandoval, J Slon-Campos, Young Chan Kim, Juthathip Mongkolsapaya, Dan H. Barouch, Stuart D. Dowall, Michael R. Boyd, Roger Hewson, Oscar R. Burrone, Peter Abbink
Publikováno v:
Vaccines
Volume 8
Issue 2
Vaccines, Vol 8, Iss 307, p 307 (2020)
Volume 8
Issue 2
Vaccines, Vol 8, Iss 307, p 307 (2020)
The flavivirus envelope protein domain III (EDIII) was an effective immunogen against dengue virus (DENV) and other related flaviviruses. Whether this can be applied to the Zika virus (ZIKV) vaccinology remains an open question. Here, we tested the e
Autor:
Xi Chen, Gang Zhou, Michael R. Boyd, Nada S. Aboelella, Donald J. Buchsbaum, Antonio Ward, Yulia Maxuitenko, Alex Coley, Gary A. Piazza, Adam B. Keeton
Publikováno v:
Drug Discov Today
Although numerous reports conclude that nonsteroidal anti-inflammatory drugs (NSAIDs) have anticancer activity, this common drug class is not recommended for long-term use because of potentially fatal toxicities from cyclooxygenase (COX) inhibition.
Autor:
Sung-Youl Ko, John R. Mascola, Barney S. Graham, Yan-Jang S. Huang, Eun Sung Yang, Martha Nason, Yaroslav Tsybovsky, Kaitlyn M. Morabito, John R. Gallagher, Christina R. DeMaso, Theodore C. Pierson, Dan H. Barouch, Mark G. Lewis, David N. Gordon, Mario Roederer, Michael R. Boyd, Hanne Andersen, Richard G. Jarman, Kimberly A. Dowd, Leda R. Castilho, John-Paul Todd, Kenneth H. Eckels, Stephen Higgs, Ramya Nityanandam, Dana L. Vanlandingham, Wing-Pui Kong, Audray K. Harris, Xuejun Chen, Rebecca S. Pelc, Peter Abbink, Rafael De La Barrera
Publikováno v:
Science
A DNA vaccine candidate for Zika The ongoing Zika epidemic in the Americas and the Caribbean urgently needs a protective vaccine. Two DNA vaccines composed of the genes that encode the structural premembrane and envelope proteins of Zika virus have b
Autor:
David Jetton, Christine A. Bricault, Ramya Nityanandam, Jean Pierre Schatzmann Peron, Marinela Kirilova, Zhenfeng Li, Paolo Marinho de Andrade Zanotto, Noe B. Mercado, Michael R. Boyd, George H. Neubauer, Peter Abbink, Rafael De La Barrera, Dan H. Barouch, Alexander Badamchi-Zadeh, Kenneth H. Eckels, Joseph P. Nkolola, David Ng’ang’a, Patricia B. Giglio, M. Justin Iampietro, Stephen J. Thomas, Lori F. Maxfield, Richard G. Jarman, Nelson L. Michael, Rafael A. Larocca, Erica N. Borducchi, Edward T. Moseley
Publikováno v:
Nature
Zika virus (ZIKV) is a flavivirus that is responsible for an unprecedented current epidemic in Brazil and the Americas1,2. ZIKV has been causally associated with fetal microcephaly, intrauterine growth restriction, and other birth defects in both hum
Autor:
David Liu, Raj Gopal, Philippe Armand, Richard Stone, Nathanael S. Gray, Oleg Nodelman, Manish Gala, Catherine J. Wu, David B. Sykes, Zuzana Tothova, Marcela V. Maus, Michael R. Boyd, Ryan B. Corcoran, Bradley E. Bernstein
Publikováno v:
The Oncologist. 21:S1-S5
Autor:
Michael R. Boyd, Marinela Kirilova, Vladimir Vrbanac, Peter Abbink, Dan H. Barouch, Po-Ting Liu, Christine A. Bricault, Lawrence J. Tartaglia, Noe B. Mercado, Andrew M. Tager, Ovini Nanayakkara, Rafael A. Larocca, Alexander Badamchi-Zadeh, Michael S. Seaman
Publikováno v:
Journal of Virology
Broadly neutralizing antibodies (bNAbs) are being explored for HIV-1 prevention and cure strategies. However, administration of purified bNAbs poses challenges in resource-poor settings, where the HIV-1 disease burden is greatest. In vivo vector-base
Autor:
Michael R. Boyd, Christine A. Bricault, Dan H. Barouch, Jill Barrett, Stephen R. Walsh, Janice Tennant, Daniel F. Hoft, Stephen J. Thomas, Peter Abbink, Leyi Lin, Alison E Kosel, Azra Blazevic, Rafael De La Barrera, Keith Meyer, Michael S. Seaman, Michael Koren, Sarah L. George, Peter Dawson, Karla Mosby, Jason Thompson, James D. Brien, Jessica L Ansel, Kathryn E. Stephenson, Melissa Walsh, Kenneth H. Eckels, Andrew J. Hale, Merlin L. Robb, C Sabrina Tan, Kristin Mills, Erica L Sondergaard, Kayvon Modjarrad, Rafael A. Larocca, Trevor A Crowell, Veronica Tonwe, Richard G. Jarman, Nelson L. Michael, Anne Basil
Summary Background A safe, effective, and rapidly scalable vaccine against Zika virus infection is needed. We developed a purified formalin-inactivated Zika virus vaccine (ZPIV) candidate that showed protection in mice and non-human primates against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::478f5f6919095a3e33a6551164991dcc
https://europepmc.org/articles/PMC5884730/
https://europepmc.org/articles/PMC5884730/
Autor:
Ramya Nityanandam, Eryn Blass, Lawrence J. Tartaglia, Marinela Kirilova, Guoyan Zhao, Erica N. Borducchi, Herbert W. Virgin, David Jetton, Michael R. Boyd, Alexander Badamchi-Zadeh, Dan H. Barouch, Peter Abbink, Menzo J. E. Havenga, Rebecca Peterson, Lori F. Maxfield, Noe B. Mercado, Scott A. Handley, Zhenfeng Li, Malika Aid, Tinaye Mutetwa, Ovini Nanayakkara, Rafael A. Larocca
Publikováno v:
Journal of Virology
Human and chimpanzee adenovirus vectors are being developed to circumvent preexisting antibodies against common adenovirus vectors such as Ad5. However, baseline immunity to these vectors still exists in human populations. Traditional cloning of new
Publikováno v:
Clinical Pulmonary Medicine. 22:87-97